Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at the Cowen Healthcare Conference on March 13, ...
March 07 2018 - 6:32AM
Innovate Biopharmaceuticals, Inc. (Nasdaq:INNT), a clinical stage
biotechnology company focused on developing novel therapeutics for
autoimmune and inflammatory diseases, announced company executives
are scheduled to present at the Cowen Healthcare Conference on
Tuesday, March 13, 2018, at 8:40 am ET in the Orleans presentation
room on the 4th floor at the Boston Marriott Copley Place located
at 110 Huntington Avenue in Boston.
The presentation will be followed by a breakout session from
9:20 am to 9:50 am ET in the Hyannis Room on the 4th floor.
About Innovate Biopharmaceuticals, Inc.
(Nasdaq:INNT): Innovate is a clinical stage biotechnology company
focused on developing novel therapeutics for autoimmune and
inflammatory diseases. Innovate’s lead drug candidate, larazotide
acetate, has a mechanism of action which decreases intestinal
permeability and regulates tight junctions across the intestinal
epithelial barrier by reducing antigen trafficking, such as gliadin
fragments in celiac disease, and lipopolysaccharide (LPS) in
nonalcoholic steatohepatitis (NASH). In several diseases, including
celiac disease, NASH, inflammatory bowel diseases (IBD, Crohn’s
disease and ulcerative colitis), irritable bowel syndrome (IBS),
type 1 diabetes mellitus (T1DM), chronic kidney disease (CKD),
intestinal permeability is increased. To the company’s knowledge,
larazotide is the only drug candidate in clinical testing which
reduces intestinal permeability, also referred to as “leaky
gut.”
In celiac disease, larazotide is the only drug which has
successfully met the primary endpoint in a Phase 2b efficacy
clinical trial with statistical significance (342-patients
enrolled). Innovate successfully completed the End of Phase 2
Meeting with the FDA in 2017 and is preparing for larazotide to
begin Phase 3 registration clinical trials for celiac disease
around mid-2018. In clinical trials testing of more than 500
patients exposed to it, larazotide demonstrated a favorable safety
profile comparable to placebo for long-term chronic administration.
Larazotide has received Fast Track designation from the FDA for
celiac disease.
Forward Looking Statements
This press release includes forward-looking statements
including, but not limited to, statements related to the potential
for Innovate’s drug development pipeline candidates in treating the
diseases and conditions for which they are being developed,
Innovate’s start of clinical trials for celiac disease, NASH,
Crohn’s disease and ulcerative colitis, and Innovate’s ability to
develop future collaborations. The forward-looking statements
contained in this press release are based on management’s current
expectations and are subject to substantial risks, uncertainty and
changes in circumstances. Actual results may differ materially from
those expressed by these expectations due to risks and
uncertainties, including, among others, those related to our
ability to obtain additional capital on favorable terms to us, or
at all, the success, timing and cost of ongoing or future clinical
trials, the lengthy and unpredictable nature of the drug approval
process, and our ability to commercialize our product candidates if
approved. These risks and uncertainties include, but may not be
limited to, those described in our Current Report on Form 8-K filed
with the U.S. Securities and Exchange Commission (the “SEC”) on
February 2, 2018, and in any subsequent filings with the SEC.
Forward-looking statements speak only as of the date of this press
release, and we undertake no obligation to review or update any
forward-looking statement except as may be required by applicable
law.
Innovate Biopharmaceuticals, Inc.Kendyle
WoodardTel: 919-275-1933Email:
investor.relations@innovatebiopharma.com
www.innovatebiopharma.com
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Apr 2024 to May 2024
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From May 2023 to May 2024